Is ertapenem safe to use together with ciprofloxacin and levofloxacin in a patient who has a penicillin allergy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ertapenem is Safe in Patients with Penicillin Allergy

Ertapenem can be safely administered to patients with penicillin allergy without prior testing or additional precautions, regardless of whether the allergy was immediate-type (IgE-mediated) or delayed-type, and this includes concurrent use with ciprofloxacin and levofloxacin. 1

Key Evidence Supporting Safety

The 2022 Drug Allergy Practice Parameter provides strong guidance on this issue 1:

  • Cross-reactivity between carbapenems (including ertapenem) and penicillins is extremely low at 0.87% (95% CI: 0.32-2.32%) 1
  • Among 838 patients with proven penicillin allergy, carbapenem reactions occurred in only 4.3%, with only 0.3% showing potentially IgE-mediated reactions 1
  • A prospective study of 211 patients with skin test-confirmed penicillin allergy showed all patients tolerated carbapenems 1

The 2023 Dutch SWAB guideline reinforces this, stating that patients with suspected immediate-type penicillin allergy can receive any carbapenem without prior allergy testing, irrespective of severity or time since the index reaction (Strong recommendation) 2

Regarding Concurrent Fluoroquinolone Use

There is no cross-reactivity or interaction concern between ertapenem and fluoroquinolones (ciprofloxacin, levofloxacin). These are completely different drug classes with distinct chemical structures and mechanisms. The combination is commonly used together for polymicrobial infections without safety concerns.

Important Caveats

When to Exercise Caution

The FDA label warns that ertapenem should be used cautiously in patients with 3:

  • History of severe delayed cutaneous reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis)
  • Organ-involved reactions (hepatitis, nephritis, hemolytic anemia)
  • Multiple drug allergies or significant patient anxiety (consider graded challenge) 1

Critical Drug Interaction

Avoid ertapenem in patients taking valproic acid or divalproex sodium 3. Carbapenems reduce valproic acid concentrations below therapeutic range, increasing seizure risk. If ertapenem is absolutely necessary, supplemental anticonvulsant therapy is required 3.

Practical Algorithm

For patients with reported penicillin allergy needing ertapenem:

  1. Characterize the allergy type:

    • Non-severe reactions (rash, urticaria, mild symptoms): Administer ertapenem directly 1, 2
    • Severe immediate reactions (anaphylaxis, angioedema): Still safe to give ertapenem directly 1, 2
    • Severe delayed reactions (SJS/TEN, organ involvement): Consider alternative or allergist consultation
  2. Check for valproic acid use - if present, choose alternative antibiotic 3

  3. Administer ertapenem with standard monitoring - no special precautions needed beyond routine care 1

  4. Optional graded challenge only if patient has multiple drug allergies or severe anxiety 1

Why This Matters for Outcomes

Using ertapenem appropriately in penicillin-allergic patients improves morbidity and mortality by:

  • Avoiding inferior alternative antibiotics (e.g., fluoroquinolones alone, aminoglycosides) that have lower efficacy for many infections
  • Reducing risk of Clostridioides difficile infection associated with alternative broad-spectrum agents
  • Preventing development of antimicrobial resistance from suboptimal therapy
  • Reducing healthcare costs

The outdated practice of avoiding all beta-lactams in penicillin-allergic patients should be abandoned given the robust evidence showing negligible cross-reactivity with carbapenems 1, 2, 4, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.